Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Tamara Thelemann"'
Autor:
Julia Festag, Tamara Thelemann, Monika Schell, Stefanie Raith, Sven Michel, Frank Jaschinski, Richard Klar
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 21, Iss , Pp 656-669 (2020)
The adenosine axis contributes to the suppression of antitumor immune responses. The ectonucleotidase CD39 degrades extracellular adenosine triphosphate (ATP) to adenosine monophosphate (AMP), which is degraded to adenosine by CD73. Adenosine binds t
Externí odkaz:
https://doaj.org/article/42e8450dd8f7414f8e521a6e5f56c509
Autor:
Anne Sadewasser, Erik Dietzel, Sven Michel, Michael Klüver, Markus Helfer, Tamara Thelemann, Richard Klar, Markus Eickmann, Stephan Becker, Frank Jaschinski
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 16, Iss , Pp 686-697 (2019)
Ebola virus is the causative agent of Ebola virus disease, a severe, often fatal illness in humans. So far, there are no US Food and Drug Administration (FDA)-approved therapeutics directed against Ebola virus. Here, we selected the host factor Niema
Externí odkaz:
https://doaj.org/article/308c7be2e7a44d74b79da85945b8925c
Autor:
Abhishek S. Kashyap, Tamara Thelemann, Richard Klar, Sandra M. Kallert, Julia Festag, Melanie Buchi, Lisa Hinterwimmer, Monika Schell, Sven Michel, Frank Jaschinski, Alfred Zippelius
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background Cancer cells are known to develop mechanisms to circumvent effective anti-tumor immunity. The two ectonucleotidases CD39 and CD73 are promising drug targets, as they act in concert to convert extracellular immune-stimulating ATP t
Externí odkaz:
https://doaj.org/article/270e5351314041b4b9b45ed11b5860ce
Autor:
Sven Michel, Stefanie Raith, Monika Schell, Frank Jaschinski, Tamara Thelemann, Richard Klar, Julia Festag
Publikováno v:
Molecular Therapy. Nucleic Acids
Molecular Therapy: Nucleic Acids, Vol 21, Iss, Pp 656-669 (2020)
Molecular Therapy: Nucleic Acids, Vol 21, Iss, Pp 656-669 (2020)
The adenosine axis contributes to the suppression of antitumor immune responses. The ectonucleotidase CD39 degrades extracellular adenosine triphosphate (ATP) to adenosine monophosphate (AMP), which is degraded to adenosine by CD73. Adenosine binds t
Autor:
Catriona V. Nguyen-Robertson, Spencer J. Williams, D. Branch Moody, Shihan Li, Dale I. Godfrey, Sidonia B G Eckle, Dylan G.M. Smith, Tan-Yun Cheng, Tram Nguyen, Scott J. J. Reddiex, Christopher M. Harpur, Jamie Rossjohn, Elena Batleska, Tamara Thelemann, Adam P Uldrich, Ildiko Van Rhijn, Daniel G. Pellicci, Catarina F. Almeida
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 118(34), 1. National Academy of Sciences
Proc Natl Acad Sci U S A
Proc Natl Acad Sci U S A
Natural killer T (NKT) cells detect lipids presented by CD1d. Most studies focus on type I NKT cells that express semi-invariant αβ T cell receptors (TCR) and recognize α-galactosylceramides. However, CD1d also presents structurally distinct lipid
Autor:
Markus Eickmann, Anne Sadewasser, Tamara Thelemann, Frank Jaschinski, Sven Michel, Michael Klüver, Erik Dietzel, Stephan Becker, Richard Klar, Markus Helfer
Publikováno v:
Molecular Therapy. Nucleic Acids
Molecular Therapy: Nucleic Acids, Vol 16, Iss, Pp 686-697 (2019)
Molecular Therapy: Nucleic Acids, Vol 16, Iss, Pp 686-697 (2019)
Ebola virus is the causative agent of Ebola virus disease, a severe, often fatal illness in humans. So far, there are no US Food and Drug Administration (FDA)-approved therapeutics directed against Ebola virus. Here, we selected the host factor Niema
Autor:
Tamara Thelemann, Frank Jaschinski, Monika Schell, Julia Festag, S Raith, Richard Klar, Sven Michel
Publikováno v:
E-Poster Presentations.
Background The so-called adenosine axis has emerged as a promising therapeutic target pathway as high adenosine levels in the tumor microenvironment contribute to the suppression of antitumor immune responses. The ectonucleotidases CD39 and CD73 act
Autor:
Frank Jaschinski, Melanie Buchi, Tamara Thelemann, Lisa Hinterwimmer, Monika Schell, Sven Michel, Abhishek S. Kashyap, Alfred Zippelius, Sandra M. Kallert, Julia Festag, Richard Klar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Cancer cells are known to develop mechanisms to circumvent effective anti-tumor immunity. The two ectonucleotidases CD39 and CD73 are promising drug targets, as they act in concert to convert extracellular immune-stimulating ATP to adenosi
Autor:
Julia Festag, Richard Klar, Melanie Buchi, Lisa Hinterwimmer, Monika Schell, Frank Jaschinski, Sandra Kallert, Sven Michel, Tamara Thelemann, Alfred Zippelius, Abhishek S. Kashyap, Stefanie Raith
Publikováno v:
Cancer Research. 79:5021-5021
The ectonucleotidases CD39 and CD73 have emerged as promising therapeutic targets to enhance antitumor immune responses, as they act in concert to convert extracellular immune-stimulating ATP to immunosuppressive adenosine. CD39 and CD73 are expresse